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Patients with cancer receiving multicycle chemotherapy are
frequently anaemic. The aetiology of anaemia in these patients is
multifactorial. In addition to the myelosuppressive effects of
chemotherapy, direct effects on the renal tubules by these agents,
particularly platinum-based compounds, leads to a decrease in the
production of erythropoietin (EPO). This hormone is responsible
for terminal differentiation, proliferation and survival of red blood
cell precursors (Koury and Bondurant, 1990). Patients with cancer
have also been shown to have inappropriately low levels of circu-
lating EPO for their degree of anaemia, reflecting a perturbation in
this homeostatic mechanism (Miller et al, 1990). This latter
problem may be due to the inflammatory state associated with
malignancy, a form of the anaemia of chronic disease (Means,
1995; Jelkmann, 1998). Other causes of decreased erythropoiesis
in patients with cancer include radiation therapy, nutritional defi-
ciencies, and replacement of the bone marrow with tumour cells.
In addition to the direct mechanical effect of tumour cells in the
bone marrow, their elaboration or induction of inflammatory
cytokines, such as tumour necrosis factor (TNF) and interleukin-1
(IL-1), can lead to a myelophthisic process associated with fibrosis
or fatty replacement of the marrow (Argiles and Lopez-Soriano,
1999). Finally, bleeding from the tumour bed or bleeding due to a
systemic coagulopathy can contribute to anaemia in patients with
cancer. Anaemia is associated with a plethora of symptoms,
including dyspnoea and fatigue. Fatigue is the most-often reported
symptom in patients with cancer and has been found to have
severe detrimental effects on their lives (Curt, 2000). Although
fatigue often results from multiple factors in these patients,
anaemia represents a common and treatable aetiology. Studies
show a relationship among low haemoglobin values, fatigue and
poor quality of life in patients with cancer (Cella, 1998). 
If a patient develops severe or symptomatic anaemia, red blood
cell transfusions may be required, with their attendant risks to
patients with cancer. Acute transfusion reactions can occur, and
although the blood supply is safer with respect to infection than
previously, risk of transmission of infectious agents still exists
(Walker, 1987; Goodnough et al, 2000). In addition, there is some
concern that frequent red blood cell transfusions with allogeneic
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Summary Darbepoetin alfa is a novel erythropoiesis stimulating protein (NESP), which stimulates erythropoiesis by the same mechanism as
recombinant human erythropoietin (rHuEPO). NESP has been shown to be safe and efficacious in patients with chronic renal failure. NESP
is biochemically distinct from rHuEPO, due to its increased sialic acid content. NESP has an approximately 3-fold greater half-life. rHuEPO
has been shown to be safe and effective for the treatment of chemotherapy-induced anaemia. This study assessed the safety and efficacy of
NESP administered once per week, under the supervision of a physician, to patients with solid tumours who were receiving multicycle
chemotherapy for up to 12 weeks. Three dose cohorts are presented in this sequential, unblinded and dose-escalating study. Thirteen to 59
patients received NESP (0.5, 1.5 or 2.25 mcg kg–1 wk–1) in each cohort. Patients were monitored for adverse events, including antibody
formation to NESP and for effects on haemoglobin. NESP appeared to be well tolerated. Adverse events were similar across all cohorts and
were consistent with the population being studied. No antibody formation was detected over the 16-week study period and follow-up. A
dose–response relationship was evident for NESP and multiple measures of efficacy, including proportion of patients responding to NESP
and the mean change in haemoglobin by week 4 and end of treatment for NESP 0.5, 1.5 and 2.25 mcg kg–1 wk–1 cohorts (mean change in
haemoglobin at end of treatment was 1.24, 1.73 and 2.15 g dl–1 respectively). Controlled studies of this agent at higher doses and
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cancer, thereby increasing the tendency to develop infections,
hastening the time to relapse or shortening survival (Cascinu et al,
1994; Goodnough et al, 2000). 
Recombinant human erythropoietin (rHuEPO) is effective in
preventing and ameliorating treatment-related anaemia in patients
with cancer (Abels, 1992; Maraveya and Pettengell, 1998). In a
placebo-controlled study in patients with cisplatin-associated
anaemia, blood transfusions were required less often in patients
receiving rHuEPO 150 U kg–1 three times a week than in patients
receiving placebo (20% vs 56%) (Abels, 1992). Similar results
were observed in patients receiving nonplatinum-based
chemotherapy (Abels, 1992). Large community-based studies
examining the effectiveness of rHuEPO in cancer patients have
generally shown response rates in the range of 50 to 60% (Glaspy
et al, 1997; Demetri et al, 1998). One of these studies (Glaspy et al,
1997) of 2030 patients demonstrated a mean (standard deviation
(SD)) increase in haemoglobin over baseline levels of 1.8 (2.1) g
dl–1. Despite the extensive clinical experience with rHuEPO in the
oncology setting, the dose response, rapidity of the response and
pharmacokinetics of rHuEPO are not fully understood in this
population of patients. 
Darbepoetin alfa is a novel erythropoiesis stimulating protein
(NESP) that stimulates erythropoiesis in the same manner as
rHuEPO. NESP is biochemically distinct from rHuEPO, created
by site-directed mutagenesis that results in 2 more glycosylation
sites allowing for additional sialic acid. These changes signifi-
cantly increase in vivo biologic activity and are associated with a
3-fold greater terminal half-life (Egrie et al, 1997). Extensive
studies in patients with chronic renal failure have confirmed this
3-fold increase in half-life, allowing it to maintain haemoglobin
levels as well as rHuEPO despite being administered less
frequently (Macdougall et al, 1999). The prolonged half-life has
been observed in cancer patients undergoing multiple cycles of
chemotherapy (Glaspy et al, 2000), predicting that it need be
administered once per week or less. Preliminary data suggest the
possibility of administering NESP once every 3 weeks so that its
dosing can be synchronized with once every 3 week chemotherapy
regimens (Kotasek et al, 2000). 
This paper presents partial results from an ongoing dose-
escalation study of NESP in patients undergoing chemotherapy.
The primary objective of this study is to assess the safety of NESP
administered by subcutaneous injection to anaemic patients with
solid tumours who were receiving multicycle chemotherapy. In
addition, this study was designed to determine clinically effective
doses of NESP administered weekly in this setting. 
PATIENTS AND METHODS 
Patients 
The institutional review boards of the participating medical
centres approved the protocol and all patients gave written
informed consent before any study-related procedures were
performed. 
Patients were eligible for study enrolment if they were at least
18 years of age; had a solid tumour and had at least 12 additional
weeks of cyclic chemotherapy planned; were anaemic (haemoglobin
≤ 1 1 . 0gd l –1), primarily because of their cancer or chemotherapy;
and if they had adequate serum folate and vitamin B12 levels and
renal and hepatic functions. Patients were to be excluded if they
had overt bleeding or haemolysis, primary or metastatic malig-
nancy of the central nervous system; had received more than two
red blood cell transfusions within 28 days before start of study or
had received any red blood cell transfusion within 2 weeks of start
of study; had received rHuEPO therapy within 8 weeks of start of
study or any previous treatment with NESP; were pregnant, breast-
feeding, or not using adequate birth control measures; or had a
history of seizure disorder, active cardiac disease, hypertension or
a primary haematologic disorder as the cause of their present
anaemia. 
Study design 
This is an ongoing phase 1–2, multicentre, open-label, sequential
dose-escalation study in anaemic patients with solid tumours who
are receiving multicycle chemotherapy. The partial results
reported here represent 3 dose cohorts who were treated weekly
and for whom the final results are available. 
Eligible patients received one of 3 doses of NESP under the
supervision of a physician (0.5, 1.5 or 2.25 mcg kg–1 wk–1) as a
subcutaneous injection starting on the first day of chemotherapy.
Enrolment to the next higher cohort was initiated when a
minimum of 4 patients had safely completed at least 6 weeks of
treatment, as determined by a safety monitoring committee. After
safety had been determined for the 2.25 mcg kg–1 wk–1 cohort,
patients were enrolled into the 1.5 mcg kg–1 wk–1 cohort to better
define the dose–response curve. Study drug was administered
under the supervision of a physician for up to 12 weeks. 
Study drug 
Darbepoetin alfa (ARANESP™, Amgen Inc, Thousand Oaks, CA)
is a novel erythropoiesis stimulating protein (NESP), formulated
with human serum albumin. Since this was a dose-finding study,
patients receiving NESP were not allowed to increase the dose if
their haemoglobin concentrations remained stable or decreased. 
Treatment procedure 
Patients were monitored for vital signs and had complete blood
counts every week while on study. Eastern Cooperative Oncology
Group (ECOG) performance status, blood chemistries, serum iron,
iron-binding capacity, ferritin and transferrin saturation were
measured at various time points during the study. Testing for anti-
bodies to NESP and coagulation panels were done at specified
time points during the study. 
At any time during the study, the dose of NESP was withheld if
a patient’s haemoglobin level increased to > 15.0 g dl–1 (for men)
or > 14.0 g dl–1 (for women). NESP was reinstated at the next
lowest dose level, or reduced by 50% if the patient was receiving
the lowest dose level, once the haemoglobin decreased to
≤ 13.0 g dl–1. NESP was administered at this adjusted dose for the
rest of the study. Originally, the dose of NESP was reduced to the
next lowest dose level if the patient had a rapid rate of rise of
haemoglobin (i.e. an increase ³ 2.0 g dl–1 over any 28-day period
in the absence of a red blood cell transfusion). The criterion for
dose reduction was removed during the conduct of the study due to
lack of safety concern. Cohorts affected by this change are
described in the results section. 
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The primary endpoint of the study was the safety of NESP, which
was assessed in terms of adverse events and antibody formation.
Serum was collected before study drug administration to provide a
baseline for the antibody-screening assay and then at regular inter-
vals throughout the study. The screening assay was a radio-
immunoprecipitation assay used routinely in NESP studies in the
oncology and nephrology settings. Rate of rise of haemoglobin
and maximum haemoglobin values were calculated. Changes in
concomitant medications, laboratory tests and vital signs were also
examined. All patients who received at least one dose of study
drug were evaluable for the safety analysis. 
Efficacy measurements 
The potential efficacy of NESP was assessed based on the number
and proportion of patients in each treatment group who achieved a
haemoglobin response, as measured by an increase in haemo-
globin of ³ 2.0 g dl–1 from baseline in the absence of red blood cell
transfusions in the previous 28 days during the 12-week treatment
phase. The maximum change in haemoglobin from baseline during
the first 4 weeks of NESP treatment and at the end of 12 weeks of
study was assessed. In addition, the incidence of red blood cell
transfusions during week 5 through week 12 was calculated. 
Statistical analysis 
The proportion of patients achieving a haemoglobin response was
calculated using the Kaplan–Meier method. All patients who
withdrew from study early and who had not met the criteria for
response at the time of study withdrawal were censored on the day
of their last haemoglobin measurement as a non-responder. 
The proportion of patients with cancer who achieve a haemo-
globin response when treated with rHuEPO is historically 50 to
60% (Abels, 1992). Therefore, a clinically effective dose was
defined as a dose at which ³ 50% of patients achieved a haemo-
globin response, ≤ 20% of patients in the safety analysis set had
clinical sequelae associated with haemoglobin that exceeds the
highest acceptable level (> 14.0 g dl–1 for women, > 15.0 g dl–1 for
men), and ≤ 20% of patients experienced a dose-limiting toxicity.
The maximum change in haemoglobin from baseline during the
first 4 weeks of NESP therapy and the 12-week study period was
determined as another measurement of efficacy. 
Data from studies of rHuEPO indicate the effects on red blood cell
transfusion requirements are not apparent until the second month of
treatment (Abels, 1992). Therefore, the proportion of patients receiv-
ing red blood cell transfusions during weeks 5 to 12 was determined. 
RESULTS 
Subject disposition 
One hundred and seven patients have received NESP in 3 dose
cohorts (0.5, 1.5 and 2.25 mcg kg–1 wk–1) for whom final data are
available. Forty (38%) of the patients receiving NESP terminated
the study prematurely. The most common reasons for early termi-
nation included withdrawal of consent and death. Sixty-seven
(63%) of the patients completed the 12-week treatment and 
4-week follow-up portion of the study. 
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Table 1 Patient baseline demographics and clinical characteristics 
NESP (mcg kg–1 wk–1) 
0.5 (n = 13) 1.5 (n = 35) 2.25 (n = 59) All (n = 107) 
Age, years 
Mean (SD) 61.3 (13.3) 62.5 (12.2) 61.8 (10.3) 62.0 (11.2) 
Sex, n (%) 
Female 9 (69.2%) 25 (71.4%) 42 (71.2%) 76 (71.0%) 
Male 4 (30.8%) 10 (28.6%) 17 (28.8%) 31 (29.0%) 
Primary disease site, n (%) 
Breast 2 (15.4%) 11 (31.4%) 18 (30.5%) 31 (29.0%) 
Lung 1 (7.7%) 2 (5.7%) 11 (18.6%) 14 (13.1%) 
Gastrointestinal 3 (23.1%) 9 (25.7%) 14 (23.7%) 26 (24.3%) 
Gynaecologic 5 (38.5%) 4 (11.4%) 4 (6.8%) 13 (12.1%) 
Genitourinary 4 (11.4%) 1 (1.7%) 5 (4.7%) 
Other solid tumour 2 (15.4%) 5 (14.3%) 11 (18.6%) 18 (16.8%) 
ECOG performance, n (%) 
0 3 (23.1%) 12 (34.3%) 21 (35.6%) 36 (33.6%) 
1 7 (53.8%) 22 (62.9%) 33 (55.9%) 62 (57.9%) 
2 2 (15.4%) 1 (2.9%) 5 (8.5%) 8 (7.5%) 
Hgb, g dl–1
Mean (SD) 9.82 (1.03) 9.72 (1.07) 9.97 (1.01) 9.87 (1.03) 
Median 9.70 9.70 10.10 10.00 
Min, Max 8.3, 11.4 7.0, 11.5 6.9, 12.0 6.9, 12.0 
Endogenous EPO, mU ml–1
Mean (SD) 50.14 (36.28) 37.52 (22.84) 46.13 (45.32) 43.80 (38.48)
Median 44.30 31.76 29.80 31.76 
Min, Max 12.0, 123.2 12.0, 101.8 12.0, 251.1 12.0, 251.1 
ECOG = Eastern Cooperative Oncology Group; EPO = erythropoietin; Hgb = haemoglobin; SD = standard deviation. Demographic and baseline characteristics 
Baseline demographic and subject characteristics are given in
Table 1. The mean age of patients was 62.0 years; 71% of the
patients were women. Breast cancer was the most common malig-
nancy, followed by gastrointestinal and lung malignancies. More
than 80% of the patients in all groups had a performance score
≤ 1 based on the ECOG scale. 
Patients were required to have a haemoglobin level of ≤ 1 1 . 0gd l –1
at screening to participate in this study. The mean (SD) haemoglobin
was 9.87 (1.03) g dl–1. Since patients received NESP up to 11 days
after screening, some had a baseline haemoglobin > 11.0 g dl–1. 
Study drug administration 
A total of 107 patients in 3 dose cohorts received at least one dose
of NESP. The protocol stipulated that NESP be reduced if a patient
exceeded a haemoglobin threshold (14.0 g dl–1 for women and
15.0 g dl–1 for men) or if the haemoglobin increased more than
2.0 g dl–1 over any 28-day period. When it was determined that a
rapid rise in haemoglobin was not associated with any apparent
safety concerns, the latter criterion was removed after the first 30
patients in the 2.25 mcg kg–1 wk–1 cohort had completed treatment
with NESP. The remaining patients in the 2.25 mcg kg–1 wk–1
cohort and all the patients in the 1.5 mcg kg–1 wk–1 cohort were
enrolled after this dose reduction criterion had been removed. The
actual average dose delivered in each of the 3 cohorts is given in
Table 2. Only the 2.25 mcg kg–1 wk–1 cohort had a meaningful
reduction in the average dose delivered, with a mean of 2.07 mcg
kg–1 wk–1 administered. 
Safety results 
The primary endpoint of the study was safety, specifically
measured by report of adverse events and antibody formation for
NESP. Six patients (6%) died on study and six (6%) discontinued
study because of adverse events. The five most commonly
reported adverse events were fatigue (44%), nausea (32%), diar-
rhoea (29%), vomiting (25%), and anorexia (21%), all common
complaints of patients receiving cytotoxic chemotherapy. Sixteen
(15%) patients reported adverse events that were determined to be
treatment-related by the investigators. These events included
injection-site pain (7%), fever (2%), pain (2%) and limb pain
(2%). Twenty-eight (26%) patients reported a serious adverse
event; one (rectal bleeding) was attributed by the investigator to
study drug. Clinically meaningful trends were not apparent in
laboratory values. No relationship between the rate of rise of
haemoglobin, reports of hypertension as an adverse event or anti-
hypertensive medication was apparent. Similarly, no relationship
was observed between the rate of rise of haemoglobin and the inci-
dence or severity of any specific adverse event. An analysis was
done correlating the maximum change in haemoglobin to the
maximum change in blood pressure within the 14-day window of
the change in haemoglobin. As shown in Figure 1, there is no
appreciable correlation between these two parameters, suggesting
that in this population, changes in haemoglobin do not adversely
affect blood pressure. 
No antibodies to NESP were detected and no clinical sequela
indicative of antibody formation was observed. 
Efficacy results 
The percentage of patients who met the definition of haemoglobin
response (³ 2.0 g dl–1 increase over baseline) increased as the dose
of study drug increased, with 3 (23%) in the 0.5 mcg kg–1 wk–1
group, 12 (44%) in the 1.5 mcg kg–1 wk–1 group and 29 (52%) in
the 2.25 mcg kg–1 wk–1 group (Table 2). 
The mean change in haemoglobin from baseline was calculated
for the first 4 weeks and at the end of the 12-week treatment period
(Table 2). The mean values increased as the dose of NESP
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Table 2 Patient haemoglobin response to NESP and actual dose delivered 
NESP (mcg kg–1 wk–1) 
0.5 1.5 2.25 
Subjects treated, n 13 35 59 
Haemoglobin response 
Number of patients 3 12 29 
Kaplan–Meier percents (95% CI) 23 (0, 46) 44 (25, 63) 52 (39, 66
Maximum change from baseline haemoglobin, g dl–1
Through week 4, mean (95% CI) 0.26 0.63 0.82 
(0.04, 0.48) (0.40, 0.86) (0.60, 1.04) 
Through entire treatment, mean (95% CI) 1.24 1.73 2.15 
(0.72, 1.75) (1.21, 2.25) (1.77, 2.52) 
RBC transfusions from week 5 to end of treatment 
Number of patients 2 7 7 
Percent of patients (95% CI) 15 (2, 45) 20 (8, 37) 12 (5, 23)
Dose of study drug received 
Number 13 35 59 
Mean 0.48 1.51 2.07 
SD 0.05 0.01 0.31 
Median 0.50 1.51 2.24 
Q1, Q3 0.50, 0.51 1.50, 1.52 1.88, 2.25 
Min, Max 0.36, 0.51 1.47, 1.54 1.27, 2.29 
CI = confidence interval; SD = standard deviation. NESP in chemotherapy-induced anaemia 21
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Figure 1 The maximum increase between any two haemoglobin values within any 28-day period from first dose onwards plotted against the maximum change
from baseline blood pressure that occurred within 14 days of the maximum increase in haemoglobin. Increases in haemoglobin that occurred within 28 days of a
red blood cell transfusion were not considered when calculating the maximum. Panel A is a plot of diastolic blood pressure (DBP) and panel B is a plot of
systolic blood pressure (SBP)increased at both the 4-week and the 12-week endpoints,
suggesting a potential dose-dependent relationship for this
efficacy parameter. 
Overall, a relatively low rate of blood transfusion was observed
in this study (Table 2). Two (15%) patients receiving 0.5 mcg kg–1
wk–1, 7 (20%) receiving 1.5 mcg kg–1 wk–1, and 7 (12%) receiving
2.25 mcg kg–1 wk–1 required a red blood cell transfusion during
weeks 5 to 12 of the study. 
DISCUSSION 
Anaemia is an increasingly recognized cause of morbidity in
patients with cancer who are undergoing chemotherapy. The use of
rHuEPO in this setting has increased dramatically over the last few
years, as the association between improvement in haemoglobin
levels and improvement in quality of life and a reduction in fatigue
has been recognized (Glaspy et al, 1997; Demetri et al, 1998;
Gabrilove et al, 1999; Cleeland et al, 1999; Littlewood et al,
2000). Although much has been learnt regarding the potential to
benefit patients through the use of erythropoietic agents, several
questions remain including the optimal dose and schedule to maxi-
mize patient benefit; the role of oral and parenteral iron supple-
mentation in maximizing response; and the impact of successful
therapy on outcomes of chemotherapy and radiotherapy. 
This study is the first published report regarding the use of
NESP, the first of a new generation of erythropoiesis stimulating
proteins with increased half-life, in the chemotherapy-induced
anaemia setting. These are the partial results of an ongoing trial
aimed at characterizing dose response and rapidity of response and
assessing the safety profile of NESP in this setting. 
The results from this study suggest that NESP is safe when
administered to patients with anaemia who are undergoing
chemotherapy. The adverse event profile was dominated by
predictable findings (e.g. fatigue, nausea) in this population of
patients with primarily advanced malignancy receiving multicycle
chemotherapy. No unexpected trends were noted in the incidence
or severity of adverse events. The issue of the rate of rise in
haemoglobin and its association with adverse events was investi-
gated. No relationship was apparent. Specifically, hypertension and
thrombotic events, two adverse events of historical interest, were
not differentially reported for patients with a more rapid increase in
haemoglobin. These observations are consistent with the physio-
logic differences between cancer patients and those with chronic
renal failure such as volume sensitivity, reduced homeostasis of
blood pressure control and a high incidence of hypertension seen in
patients with renal failure. NESP appears to be safe at all doses
tested to date. No antibodies to NESP were detected in this study. 
The efficacy of NESP was assessed in 3 ways. First, the propor-
tion of patients who achieved a 2.0 g dl–1 increase in haemoglobin
over baseline was investigated. A dose-dependent increase in the
proportion of patients meeting this criterion was apparent.
Historically, rHuEPO has generally been associated with a 50 to
60% response rate (Abels, 1992; Glaspy et al, 1997; Demetri et al,
1998). These studies allowed for the dose of rHuEPO to be
doubled during the 6 to 8 weeks of the study if patients were not
exhibiting a response. No such dose adjustment was allowed for
the NESP doses in this study. Since the protocol stipulated dose
reductions when patients reached various haemoglobin thresholds,
the average delivered dose of NESP was less than that assigned to
the 2.25 mcg kg–1 wk–1 cohort. These patients received, on average,
only 2.07 mcg kg–1 wk–1 of NESP. Whether higher response rates
are possible with increasing doses of NESP is the subject of
ongoing studies. 
Another efficacy parameter that was assessed in this study was
the mean (SD) change in haemoglobin during the first 4 weeks and
the entire 12 weeks of the study. Again, a dose-dependent relation-
ship was suggested, with the greatest changes being associated
with the highest dose. The magnitude of the changes in this study
at higher dose levels seems consistent with that observed in the
literature (Abels, 1992; Glaspy et al, 1997) and suggests a drug
effect. 
Finally, the incidence of red blood cell transfusions was
assessed throughout the study. Since the literature suggests that
rHuEPO does not influence the incidence of transfusions during
the first month of therapy (Abels, 1992), the period of week 5 to
week 12 was analysed. No relationship to dose across the 3 cohorts
was apparent with respect to this outcome; however, in general,
the transfusion rates were low. 
Since the data presented are partial results from an ongoing
study, limited conclusions can be drawn. First, the lack of control
data makes it difficult to generalize these findings to other patient
populations, or to the published data with respect to rHuEPO. The
outcome of the higher doses studied seems to be comparable to
what would be expected with rHuEPO, but patient selection could
have confounding influences on this determination. A dose-
dependent relationship with efficacy parameters (e.g. proportion
of patients responding and mean change in haemoglobin) is
apparent, suggesting that these findings are due to the effects of
the study drug. Although the design of this study allows for evalu-
ation of the 3 specified doses, it does not provide information that
would allow extrapolation of the effect of increasing the dose of
NESP in patients who do not exhibit a haemoglobin response, as is
the standard for rHuEPO. The dose-dependent increase in haemo-
globin outcomes suggests that such a dose increase may lead to
higher response rates, but this speculation must be confirmed in a
study designed to assess this endpoint. Finally, although rHuEPO
is currently approved for administration three times per week in
the United States, it is standardly being administered at 40 000 U
wk–1 (Gabrilove et al, 1999). The 3-fold increase in the half-life of
NESP compared with rHuEPO as demonstrated in the nephrology
setting was confirmed in the oncology setting (Heatherington et al,
2001) and suggests that NESP can be administered less frequently.
Schedules should be explored in which NESP is given less
frequently than the weekly schedule reported in this study, and
higher doses of NESP need to be explored to further investigate
the dose–response relationship in a well-controlled study. 
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